- Home
- GCO vs ANL Comparison
GCO vs ANL Comparison
Compare GCO & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GCO | ANL |
|---|---|---|
| Founded | 1924 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 286.0M | 293.4M |
| IPO Year | 1994 | 2022 |
Fundamental Metrics
Financial Performance| Metric | GCO | ANL |
|---|---|---|
| Price | $27.81 | $6.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $33.00 | $16.00 |
| AVG Volume (30 Days) | ★ 212.0K | 166.0K |
| Earning Date | 03-06-2026 | 04-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 171.84 | N/A |
| EPS | ★ 1.25 | N/A |
| Revenue | ★ $2,606,898,000.00 | N/A |
| Revenue This Year | $0.78 | N/A |
| Revenue Next Year | $2.12 | N/A |
| P/E Ratio | $22.38 | ★ N/A |
| Revenue Growth | ★ 13.71 | N/A |
| 52 Week Low | $16.19 | $0.88 |
| 52 Week High | $38.95 | $12.09 |
Technical Indicators
Market Signals| Indicator | GCO | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 54.80 | 37.90 |
| Support Level | $27.02 | $1.36 |
| Resistance Level | $29.79 | $9.98 |
| Average True Range (ATR) | 1.30 | 0.78 |
| MACD | 0.41 | -0.23 |
| Stochastic Oscillator | 77.18 | 11.23 |
Price Performance
Historical ComparisonAbout GCO Genesco Inc.
Genesco Inc. sells footwear, headwear, sports apparel, and accessories through four main segments. The Journeys Group generates the highest revenue, encompassing the Journeys, Journeys Kidz, and Little Burgundy brands, along with e-commerce and catalog sales. The Schuh Group targets teenagers and young adults aged 16 to 24, focusing on casual and athletic footwear. The Johnston & Murphy Group operates retail shops and factory stores across the United States. Finally, the Genesco Brands Group designs and sources licensed footwear for brands like Levi's, Dockers, and G.H. Bass.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.